BR0110246A - Amidas de ácido benzóico substituìdas e uso das mesmas para inibição de angiogênese - Google Patents

Amidas de ácido benzóico substituìdas e uso das mesmas para inibição de angiogênese

Info

Publication number
BR0110246A
BR0110246A BR0110246-0A BR0110246A BR0110246A BR 0110246 A BR0110246 A BR 0110246A BR 0110246 A BR0110246 A BR 0110246A BR 0110246 A BR0110246 A BR 0110246A
Authority
BR
Brazil
Prior art keywords
benzoic acid
acid amides
substituted benzoic
angiogenesis inhibition
angiogenesis
Prior art date
Application number
BR0110246-0A
Other languages
English (en)
Inventor
Andreas Huth
Dieter Seidelmann
Karl-Heinz Thierauch
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0110246A publication Critical patent/BR0110246A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"AMIDAS DE áCIDO BENZóICO SUBSTITUìDAS E USO DAS MESMAS PARA INIBIçãO DE ANGIOGêNESE". A invenção refere-se a amidas de ácido benzóico substituídas da fórmula (1) e ao uso das mesmas como medicamento para tratamento de doenças, que são provocada por angiogênese persistente, bem como aos produtos intermediários das mesmas, para produção das amidas de ácido benzóico.
BR0110246-0A 2000-04-25 2001-04-24 Amidas de ácido benzóico substituìdas e uso das mesmas para inibição de angiogênese BR0110246A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10021246A DE10021246A1 (de) 2000-04-25 2000-04-25 Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
PCT/EP2001/004627 WO2001081311A1 (de) 2000-04-25 2001-04-24 Substituierte benzoesäureamide und deren verwendung zur hemmung von angiogenese

Publications (1)

Publication Number Publication Date
BR0110246A true BR0110246A (pt) 2003-03-05

Family

ID=7640467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110246-0A BR0110246A (pt) 2000-04-25 2001-04-24 Amidas de ácido benzóico substituìdas e uso das mesmas para inibição de angiogênese

Country Status (28)

Country Link
US (1) US20110009447A1 (pt)
EP (1) EP1280776B1 (pt)
JP (1) JP2004512259A (pt)
KR (1) KR100904101B1 (pt)
CN (1) CN1285578C (pt)
AT (1) ATE446288T1 (pt)
AU (2) AU5227201A (pt)
BG (1) BG107212A (pt)
BR (1) BR0110246A (pt)
CA (1) CA2406392C (pt)
CZ (1) CZ20023545A3 (pt)
DE (2) DE10021246A1 (pt)
EE (1) EE200200609A (pt)
ES (1) ES2334433T3 (pt)
HK (1) HK1056559A1 (pt)
HR (1) HRP20020933A2 (pt)
HU (1) HUP0300920A1 (pt)
IL (1) IL152292A0 (pt)
MX (1) MXPA02010559A (pt)
NO (1) NO325445B1 (pt)
NZ (1) NZ521681A (pt)
PL (1) PL358457A1 (pt)
RU (1) RU2353618C2 (pt)
SK (1) SK15222002A3 (pt)
UA (1) UA82980C2 (pt)
WO (1) WO2001081311A1 (pt)
YU (1) YU71102A (pt)
ZA (1) ZA200209494B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
WO2005015158A2 (en) 2003-08-06 2005-02-17 Senomyx Inc. T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
TW200529812A (en) * 2003-12-26 2005-09-16 Chugai Pharmaceutical Co Ltd Benzamide derivatives
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US7915443B2 (en) * 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
EA027573B1 (ru) 2005-12-23 2017-08-31 Ариад Фармасьютикалз, Инк. Бициклические гетероарильные соединения
CN105152940A (zh) 2006-04-21 2015-12-16 西诺米克斯公司 含有高效鲜味调料的可食用组合物及其制备方法
EP2024342A2 (en) * 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
CA2650273C (en) 2006-05-08 2016-06-07 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
KR20090018104A (ko) 2006-05-08 2009-02-19 어리어드 파마슈티칼스, 인코포레이티드 아세틸렌계 헤테로아릴 화합물
EP2120964A2 (en) 2006-12-15 2009-11-25 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
KR20120137513A (ko) 2007-04-20 2012-12-21 어큐셀라 인코포레이티드 안과 질환 및 장애 치료용 스티레닐 유도체 화합물
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
DK2346827T3 (da) 2008-08-27 2014-02-03 Leo Pharma As Pyridinderivater som VEGFR-2 receptor og proteintyrosinkinasehæmmere
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010144394A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Benzyl substituted triazine derivatives and their therapeutical applications
US9078902B2 (en) 2009-06-09 2015-07-14 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US8623889B2 (en) 2010-12-17 2014-01-07 Genentech, Inc. Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
KR20160110357A (ko) 2013-11-15 2016-09-21 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Ｅｂｎａ１ 억제제 및 그의 사용 방법
WO2016183534A1 (en) 2015-05-14 2016-11-17 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
CN106740403A (zh) * 2017-03-21 2017-05-31 西北工业大学 一种液氮动力输出系统及混合动力冷链运输车
EP3793546A4 (en) 2018-05-17 2021-12-08 The Wistar Institute CRYSTALLINE FORMS OF EBNA1-INHIBITOR AND METHOD OF MANUFACTURING AND USING THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643265C3 (de) * 1967-12-22 1978-08-31 C.H. Boehringer Sohn, 6507 Ingelheim Kernsubstituierte 2-Aminomethylbenzhydrole, Verfahren zu deren Herstellung und Arzneimittel auf der Basis dieser Verbindungen
JPH02218654A (ja) * 1988-10-12 1990-08-31 Ono Pharmaceut Co Ltd 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
US5863455A (en) * 1997-07-14 1999-01-26 Abb Power T&D Company Inc. Colloidal insulating and cooling fluid
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
CA2336848A1 (en) * 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
JP2002523459A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤
EP1126842A2 (en) * 1998-11-06 2001-08-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo

Also Published As

Publication number Publication date
DE10021246A1 (de) 2001-10-31
AU2001252272B2 (en) 2007-03-29
EP1280776A1 (de) 2003-02-05
MXPA02010559A (es) 2003-03-10
IL152292A0 (en) 2003-05-29
ZA200209494B (en) 2004-07-14
YU71102A (sh) 2006-03-03
CA2406392C (en) 2011-08-30
US20110009447A1 (en) 2011-01-13
CN1285578C (zh) 2006-11-22
KR100904101B1 (ko) 2009-06-24
WO2001081311A1 (de) 2001-11-01
EP1280776B1 (de) 2009-10-21
AU5227201A (en) 2001-11-07
HRP20020933A2 (en) 2005-02-28
EE200200609A (et) 2004-04-15
HUP0300920A1 (hu) 2003-07-28
CA2406392A1 (en) 2001-11-01
ATE446288T1 (de) 2009-11-15
DE50115189D1 (de) 2009-12-03
RU2353618C2 (ru) 2009-04-27
KR20020093946A (ko) 2002-12-16
PL358457A1 (en) 2004-08-09
CZ20023545A3 (cs) 2003-02-12
NO20025102L (no) 2002-12-17
NO20025102D0 (no) 2002-10-24
UA82980C2 (ru) 2008-06-10
JP2004512259A (ja) 2004-04-22
NZ521681A (en) 2006-03-31
CN1426396A (zh) 2003-06-25
ES2334433T3 (es) 2010-03-10
BG107212A (bg) 2003-05-30
NO325445B1 (no) 2008-05-05
HK1056559A1 (en) 2004-02-20
SK15222002A3 (sk) 2003-06-03

Similar Documents

Publication Publication Date Title
BR0110246A (pt) Amidas de ácido benzóico substituìdas e uso das mesmas para inibição de angiogênese
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
BR0116047A (pt) Imidazoquinolinas substituìdas de éter heterocìclico
BR0110486A (pt) Antranilamidas e sua aplicação como medicamento
BR0116217A (pt) Quinolonas antimicrobianas, composição farmacêutica, bem como aplicação farmacêutica das referidas quinolonas
BR0116067A (pt) Derivado de metanossulfonamido-benzofurano, seu processo de preparação e sua utilização como intermediário de sìntese
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
ATE263157T1 (de) Nematizide trifluorbutene
TR200101513T2 (tr) Benzamid türevleri ve bunların APOB-100 salgılama inhibitörleri olarak kullanımları
MEP10408A (en) Platinum derivative pharmaceutical formulations
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0300936A (pt) Isononiléster de ácido benzóico e seu uso
BR0211502A (pt) Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
PA8516901A1 (es) "5-cloro-3-(4-metansulfonilfenilo)-6'-metil-[2,3'] bipiridinil o en forma cristalina pura y proceso para la síntesis"
BR0113425A (pt) Aminoalquilbenzoil-benzofuranos ou benzotiófenos, processo de preparação dos mesmos e as composições que os contêm
SE9901077D0 (sv) Novel use
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
BR0114437A (pt) Derivados de acido propiÈnico
SE9801494D0 (sv) Novel use
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
YU37597A (en) New pyranosid derivatives
BR0108087A (pt) Método e composições para o tratamento de uma doença inflamatória
ATE284882T1 (de) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.